Respiro Diagnostics
Develops AI-enabled lung diagnostic tools to help healthcare providers assess and manage respiratory conditions.
Overview
Respiro Diagnostics is advancing lung diagnostics with an AI-focused approach for respiratory healthcare. The company targets clinical settings where faster or more accessible assessment of lung health could support decision-making, though the disclosed round does not detail its product architecture or regulatory status. The company raised £1M in a pre-seed round announced July 8, 2026, providing early capital to further develop its diagnostic platform. Its positioning sits at the intersection of AI and pulmonary care, with differentiation centered on a dedicated focus on lung diagnostics rather than broad digital health.
Funding History
Respiro Diagnostics secures £1M to advance lung diagnostics
Frequently Asked Questions
- How much funding does AI Funding track for Respiro Diagnostics?
- AI Funding tracks £1M for Respiro Diagnostics across 1 funding round in this database.
- What does Respiro Diagnostics do?
- Respiro Diagnostics is advancing lung diagnostics with an AI-focused approach for respiratory healthcare. The company targets clinical settings where faster or more accessible assessment of lung health could support decision-making, though the disclosed round does not detail its product architecture or regulatory status. The company raised £1M in a pre-seed round announced July 8, 2026, providing early capital to further develop its diagnostic platform. Its positioning sits at the intersection of AI and pulmonary care, with differentiation centered on a dedicated focus on lung diagnostics rather than broad digital health.
- Where is Respiro Diagnostics headquartered?
- Respiro Diagnostics is headquartered in San Francisco, CA.
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.